{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000120","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.991610+00:00","generated_at":"2026-06-07T13:49:52.673827+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14","bullets":["FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.","FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.","Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.","Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.","Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000120","json":"https://secwatch.observer/filing/0000078003-23-000120.json","markdown":"https://secwatch.observer/filing/0000078003-23-000120.md","text":"https://secwatch.observer/filing/0000078003-23-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/0000078003-23-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/pfe-20231213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:49:52.673827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}